Dealmaking 1996: The Year in Review
Executive SummaryWhile the drug industry continued to shun acquisitions in favor of alliances, service and device companies see mergers as the only way to go. Can diagnostics, still stubbornly unconsolidated, be far behind?
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.